University of Pittsburgh

Davol Inc.

George S Hussey

Stephen Francis Badylak

Devang Vijay Shah

Lindsey Tamiko Saldin

Juan Diego Naranjo Gutierrez

Quan Liu

Peter Maughan Crapo

Michael Brandt Steketee

Yolandi Van Der Merwe

Luai Huleihel

Mark Hikaru Murdock

Brian Sicari

Catalina Pineda Molina

Zhongqiang Zhang

Jenna Lynn Dziki

Heth Turnquist

Anne E Faust

Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63CD81. In additional embodiments, methods are disclosed for increasing myoblast differentiation.

Matrix bound vesicles (MBVS) containing IL-33 and their use

Articles and methods involving soft tissue repair implants comprising 2-hydroxybutyrate, 3-hydroxybutyrate, 4-hydroxybutyrate, and/or their conjugate acids are generally provided. The 2-hydroxybutyrate, 3-hydroxybutyrate, 4-hydroxybutyrate, and/or the conjugate acid(s) of 2-hydroxybutyrate, 3-hydroxybutyrate, and 4-hydroxybutyrate may be provided in a therapeutically-effective amount for reducing or preventing microbial infection.

Soft tissue repair implants comprising hydroxybutyrate

Methods are disclosed herein for producing a mammalian acoustic extracellular matrix (ECM) hydrogel. In further embodiments, mammalian acoustic ECM hydrogels are disclosed that are produced using the disclosed methods. Also disclosed is a mammalian acoustic ECM hydrogel, wherein the hydrogel is thermoreversible. Methods of using these acoustic ECM hydrogels are also disclosed.

Acoustic extracellular matrix hydrogels and their use

A composition is disclosed herein that includes isolated ECM-derived nanovesicles and a pharmaceutically acceptable carrier. Methods are producing the ECM-derived nanovesicles are also disclosed. These ECM-derived nanovesicles can be included in pharmaceutical compositions, bioscaffolds, and devices. Methods for using these ECM-derived nanovesicles are provided.

Matrix bound nanovesicles and their use

Methods are disclosed herein for increasing retinal ganglion cell survival in a subject in need thereof. These methods include selecting a subject in need of increased retinal ganglion cell survival and administering a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix (MBVs) to the subject.

Ocular applications of matrix bound vesicles (MBVs)

Methods are disclosed for reducing the proliferation of a tumor cell, increasing apoptosis of a tumor cell, and/or decreasing migration of a tumor cell. These methods include contacting the tumor cell with an effective amount of solubilized ECM or a soluble fraction of extracellular matrix (ECM), thereby reducing the proliferation of the tumor cell, increasing apoptosis of the tumor cell, and/or decreasing migration of the tumor cell. Methods are also disclosed for treating a subject with a tumor. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a soluble fraction of an ECM and a pharmaceutically acceptable carrier, thereby treating the tumor in the subject. In specific non-limiting examples, the tumor is a glioma and/or the ECM hydrogel is a urinary bladder ECM hydrogel.

Extracellular matrix (ECM) hydrogel and soluble fraction thereof for the treatment of cancer

Growing community of inventors

Cranberry Township, PA, United States of America

George S Hussey